DACLIZUMAB IS A HUMANISED MONOCLONAL MURINE ANTIBODY THAT FUNCTIONS AS AN INTERLEUKIN-2 RECEPTOR ANTAGONIST BY BINDING TO THE ALPHA CHAIN (CD25 ANTIGEN, TAC SUBUNIT) OF THE INTERLEUKIN-2 RECEPTOR ON THE SURFACE OF ACTIVATED T-LYMPHOCYTES. IT IS USED IN THE PREVENTION OF ACUTE GRAFT REJECTION AFTER KIDNEY TRANSPLANTATION AS PART OF AN IMMUNOSUPPRESSIVE REGIMEN THAT INCLUDES CICLOSPORIN AND CORTICOSTEROIDS.